BackAeglea BioTherapeutics Overview

Aeglea BioTherapeutics Long Term Debt

Track Aeglea BioTherapeutics's long-term debt ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$0.00

Peer average

Loading

Aeglea BioTherapeutics Long Term Debt History

Loading

Aeglea BioTherapeutics vs. peers: Long Term Debt Comparison

Loading

Aeglea BioTherapeutics Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Aeglea BioTherapeutics (AGLE) FAQ

Aeglea BioTherapeutics (AGLE) currently reports a long-term debt of $0 as of June 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore Aeglea BioTherapeutics's long-term debt history and peer comparisons.

Aeglea BioTherapeutics's long-term debt changed from $0 to $0 (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Aeglea BioTherapeutics reported $0 in long-term debt as of June 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Aeglea BioTherapeutics, and consider following AGLE for alerts when major investors trade the stock.

Aeglea BioTherapeutics is classified in the Healthcare sector. On long-term debt, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AGLE with unrelated industries.